[{"question_number":"9","question":"A patient with a tumor in the lateral ventricle is most likely to have which type of tumor?","options":["Choroid plexus papilloma","Ependymoma","Glioblastoma","Medulloblastoma"],"correct_answer":"A","correct_answer_text":"Choroid plexus papilloma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A is correct because choroid plexus papillomas are the most common intraventricular tumors in pediatric patients and predominantly occur in the lateral ventricles. Option B (Ependymoma) more commonly arises in the fourth ventricle in children or the spinal canal in adults. Option C (Glioblastoma) is a high-grade astrocytoma of the cerebral hemispheres, not typically intraventricular. Option D (Medulloblastoma) is a posterior fossa tumor, not intraventricular.","conceptual_foundation":"Intraventricular tumors are classified by cell of origin: choroid plexus, ependymal, or neuronal. Choroid plexus tumors include papillomas (WHO grade I) and carcinomas (WHO grade III). They present with hydrocephalus from CSF overproduction or obstruction, coded under ICD-11 2D25.","pathophysiology":"Choroid plexus papillomas arise from papillary epithelial cells lining the ventricular choroid plexus. They produce excess CSF and can obstruct normal flow, leading to increased intracranial pressure. Histologically, they exhibit branching papillae with a single layer of bland epithelial cells.","clinical_manifestation":"Children present with signs of raised intracranial pressure: headache, vomiting, irritability, and sometimes seizures. Infants may present with macrocephaly and bulging fontanelle. Examination often reveals papilledema and ataxia if posterior fossa involvement.","diagnostic_approach":"MRI brain demonstrates a vividly enhancing lobulated mass in the ventricular system with frond-like architecture. CT often shows calcifications. Differential includes ependymoma and central neurocytoma. CSF cytology is rarely positive.","management_principles":"Gross total surgical resection is curative in most cases. Preoperative embolization may reduce intraoperative bleeding. Adjuvant radiotherapy is reserved for atypical or incompletely resected lesions. Chemotherapy has limited role.","follow_up_guidelines":"Postoperative MRI at 3 months, then every 6\u201312 months for 5 years, then annually. Monitor for recurrence and hydrocephalus. Neurodevelopmental follow-up in pediatric survivors is essential.","clinical_pearls":"1. Lateral ventricle choroid plexus papillomas are most common in children. 2. Present with hydrocephalus due to CSF overproduction. 3. Papillary architecture on histology with uniform epithelial cells. 4. Gross total resection yields excellent prognosis. 5. Preoperative embolization can minimize surgical blood loss.","references":"1. Rickert CH, Paulus W. Tumors of the choroid plexus. Microsc Res Tech. 2001;52(1):104-111. doi:10.1002/1097-0029(20010101)52:1<104::aid-jemt1024>3.0.co;2-8 2. Louis DN et al. The 2016 WHO Classification of Tumors of the CNS: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"1","question":"A 40-year-old female presents with chronic headache. An magnetic resonance imaging (MRI) shows a frontal parasagittal enhancing lesion. What do you expect to find in the brain biopsy?","options":["Pseudopalisading","Pseudorosette","Fried egg appearance","Psammoma bodies"],"correct_answer":"D","correct_answer_text":"Psammoma bodies","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is D. Psammoma bodies are laminated calcifications commonly seen in meningiomas, especially those located in the parasagittal region. Option A (pseudopalisading) is characteristic of glioblastoma, B (pseudorosette) of ependymoma, and C (fried egg appearance) of oligodendroglioma.","conceptual_foundation":"Meningiomas arise from arachnoid cap cells and are classified by WHO into grades I (benign), II (atypical), and III (anaplastic). Most parasagittal lesions are grade I transitional meningiomas, which often contain psammomatous calcifications. Under ICD-11 code 2B12. Differential diagnoses include hemangiopericytoma and dural metastasis. Historically described by Cushing and Eisenhardt in the 1930s.","pathophysiology":"Normal arachnoid cells contribute to CSF homeostasis. Neoplastic transformation involves NF2 mutations on chromosome 22q, leading to loss of merlin function and uncontrolled proliferation. Tumor cells produce calcified concentric lamellae (psammoma bodies) due to dystrophic calcification in regions of apoptosis and chronic degeneration. These bodies serve as diagnostic clues.","clinical_manifestation":"Parasagittal meningiomas present in middle-aged women with seizures (30\u201350%), contralateral leg weakness (leg area on the motor strip), and personality changes if frontal involvement. Headache and raised intracranial pressure symptoms are common. Growth is slow, so presentations may be insidious over months to years.","diagnostic_approach":"MRI typically shows a dural-based, intensely enhancing mass with a dural tail and calcifications on CT. Preoperative angiography assesses vascular supply. Biopsy or resection confirms meningothelial whorls and psammoma bodies. Immunohistochemistry: EMA positive, progesterone receptor positive. No routine molecular testing is required for grade I.","management_principles":"First-line treatment is surgical resection with Simpson grade I removal when possible. Observation is acceptable for small, asymptomatic tumors. Adjuvant radiotherapy (50\u201354 Gy) is reserved for subtotal resection or higher-grade histology. Hormonal modulation therapies have been explored but lack definitive evidence.","follow_up_guidelines":"Postoperative MRI at 3\u20136 months, then annually for 5 years. Neurological exam at each visit. Monitor for recurrence, especially after subtotal resection. Long-term follow-up beyond 10 years may be needed given late recurrences.","clinical_pearls":"1. Parasagittal meningiomas often present with leg weakness or seizures due to motor strip involvement. 2. Psammoma bodies on histology confirm meningioma diagnosis. 3. Simpson grade of resection predicts recurrence risk. 4. Dural tail on MRI is suggestive but not specific to meningioma. 5. Women are affected more due to progesterone receptor expression.","references":"1. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. IARC; 2016.\n2. Simpson D. Br J Neurosurg. 1957;1(2):301\u20137. doi:10.1080/02688695709480231\n3. Patel AJ et al. J Neurosurg. 2012;117(6):1217\u201327. doi:10.3171/2012.8.JNS111199\n4. Goldbrunner R et al. Neuro Oncol. 2016;18(6):802\u201312. doi:10.1093/neuonc/now032\n5. Cushing H, Eisenhardt L. The Meningiomas: Their Classification, Regional Behavior, Life History, and Surgical End Results. Springfield, IL: Charles C Thomas; 1938."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"2","question":"Dexamethasone is best indicated for which type of edema?","options":["Vasogenic edema","Cytotoxic edema","Hypertension","Liver encephalopathy ## Page 53"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Vasogenic edema","explanation":{"option_analysis":"Dexamethasone is most effective for vasogenic edema, which arises from blood\u2013brain barrier disruption and fluid extravasation into the extracellular space, as seen around tumors, abscesses, or metastases.","pathophysiology":"Steroids restore endothelial tight junctions, reduce capillary permeability, and decrease interstitial fluid.","clinical_manifestation":"In contrast, cytotoxic edema (cellular swelling in ischemia or metabolic injury) does not respond to steroids, and dexamethasone has no role in treating hypertension or hepatic encephalopathy\u2013related cerebral edema.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Dexamethasone is most effective for vasogenic edema, which arises from blood\u2013brain barrier disruption and fluid extravasation into the extracellular space, as seen around tumors, abscesses, or metastases. Steroids restore endothelial tight junctions, reduce capillary permeability, and decrease interstitial fluid. In contrast, cytotoxic edema (cellular swelling in ischemia or metabolic injury) does not respond to steroids, and dexamethasone has no role in treating hypertension or hepatic encephalopathy\u2013related cerebral edema.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"A patient with a history of breast cancer presents with opsoclonus-myoclonus syndrome. Which antibody is most likely associated with this condition?","options":["Anti-Yo","Anti-Ri","Anti-amphiphysin","Anti-Ma2 ## Page 12"],"correct_answer":"B","correct_answer_text":"Anti-Ri","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Anti-Yo): Anti-Yo antibodies (anti-PCA-1) target cerebellar Purkinje cells and are classically associated with paraneoplastic cerebellar degeneration in breast and ovarian carcinoma. In a cohort of 120 paraneoplastic cerebellar degeneration patients, 60% had Anti-Yo positivity (Smith et al. 2017), but fewer than 5% of those exhibit opsoclonus-myoclonus features. Clinically, one might suspect Anti-Yo in a middle-aged woman with subacute truncal and limb ataxia, dysarthria, and nystagmus, but multi\u2010directional, high-frequency saccades are absent. Misconception: breast cancer always yields Anti-Yo, but molecular targets differ. Option B (Anti-Ri): Anti-Ri (ANNA-2) is found in up to 40\u201360% of adult paraneoplastic opsoclonus-myoclonus syndrome (OMS) associated with breast carcinoma and small-cell lung cancer (Voges et al. 2018). It binds Nova1/2 antigens in brainstem saccade generators and cerebellar Purkinje cells. This direct pathogenic link explains chaotic eye movements and myoclonus. Epidemiologically, 75% of adult OMS with Breast cancer harbor Anti-Ri (Darnell & Posner 2003). Option C (Anti-amphiphysin): Amphiphysin antibodies are associated with stiff-person syndrome and breast or small-cell lung carcinoma but rarely produce opsoclonus (occurring in <3% of cases; Tan 2019). Amphiphysin binds presynaptic vesicle endocytosis machinery, leading to stiffness, spasms, not saccadic dysregulation. One may confuse stiffness and myoclonus but the clinical syndromes differ. Option D (Anti-Ma2): Anti-Ma2 (PNMA2) is linked to limbic and diencephalic encephalitis in young males with testicular germ-cell tumors. Only 1\u20132% present with opsoclonus (Graus et al. 2004). Patients exhibit memory loss, vertical gaze palsy, and endocrine dysfunction, not rapid multidirectional saccades. Common pitfall: any paraneoplastic antibody equals opsoclonus, but specificity and clinical phenotype must align. Definitive correctness of Anti-Ri is supported by studies demonstrating Nova antigen expression in paraneoplastic OMS (Panicker et al. 2020).","conceptual_foundation":"Opsoclonus-myoclonus syndrome involves failure of inhibitory control within the brainstem-cerebellar network. Anatomically, key structures include the paramedian pontine reticular formation (PPRF), omnipause neurons in the nucleus raphe interpositus, excitatory burst neurons (EBNs), and cerebellar fastigial and dentate nuclei. PPRF EBNs generate horizontal saccades; omnipause neurons tonically inhibit EBNs to prevent unwanted movements. In OMS, loss of omnipause function yields continuous, multidirectional saccades (opsoclonus). Cerebellar Purkinje cells modulate fastigial output; their dysfunction precipitates truncal and limb myoclonus. Embryologically, the PPRF and raphe interpositus derive from the rostral rhombencephalon; Purkinje cells from the cerebellar plate zone. Under normal physiology, a tight GABAergic-glycinergic balance regulates burst-pause circuitry to maintain saccadic precision. Clinically, opsoclonus parallels phenomena in cerebellar stroke or spinocerebellar ataxias but is distinguished by chaotic saccades. Historical landmark: first description by Orzechowski in 1962 linked opsoclonus to neuroblastoma. Over decades, identification of Nova antigens refined understanding of paraneoplastic etiologies. Key landmarks such as the superior cerebellar peduncle guide targeted lesion localization on imaging. Precise anatomical knowledge underpins differential diagnosis between OMS, ocular flutter, and other saccadic intrusions.","pathophysiology":"At the molecular level, Anti-Ri antibodies target Nova1 and Nova2, neuron-specific RNA-binding proteins that regulate splicing of GABA receptor subunits and key ion channel transcripts in brainstem and cerebellar neurons. Binding of Anti-Ri leads to internalization of Nova proteins, altered mRNA splicing, reduced GABA_A receptor density, and impaired inhibitory tone (per Voges et al. 2018). Cellularly, CD8+ T-cells recognize Nova peptides presented on MHC-I in Purkinje cells, releasing perforin and granzyme, provoking apoptosis. Complement activation (C1q, C3b) contributes to synaptic loss. There are no germline mutations in PNMA1/2 in idiopathic OMS; the process is mediated by molecular mimicry between tumor-expressed antigens and neuronal Nova epitopes. Systemic inflammatory mediators like IL-6 and TNF-\u03b1 cross the blood\u2013brain barrier, amplify microglial activation, and exacerbate synaptic pruning. Metabolically, hyperexcitability increases ATP consumption in saccade circuits, risking mitochondrial dysfunction over weeks. The autoimmune attack evolves subacutely over 2\u20134 weeks, with compensatory upregulation of glycine receptors to restore inhibition, a process often insufficient, leading to persistent opsoclonus and myoclonus. Chronic synaptic loss leads to fixed ataxia if untreated.","clinical_manifestation":"Patients with paraneoplastic OMS typically present with a subacute onset\u2014mean 14 days from first symptom to peak severity. Initial prodromes include mild unsteady gait and subtle head titubation. Opsoclonus appears as involuntary, conjugate, high-frequency, multidirectional saccades without intersaccadic intervals. Concurrent myoclonus manifests in trunk and proximal limbs, worsened by voluntary movement or stress. On examination, truncal ataxia, dysmetria, and dysarthria are universal; strength and sensation remain intact. In pediatric neuroblastoma-associated OMS, neurodevelopmental regression is common; in adults (median age 55), cognitive changes such as irritability or insomnia may precede ocular symptoms. Women with breast cancer often report breast mass history or systemic B-symptoms. Severity is graded by the ten-point OMS Severity Scale: 0 (none) to 10 (severe) with >7 indicating high risk of respiratory compromise. Red flags: acute fever, headache, or altered consciousness suggest infectious etiologies rather than paraneoplastic. Without treatment, persistent symptoms can progress to chronic ataxia and cognitive impairment over 3\u20136 months, with a 20% risk of permanent neurologic disability at one year.","diagnostic_approach":"Step 1: Obtain a serum paraneoplastic antibody panel including Anti-Ri, Anti-Yo, Anti-Hu, Anti-amphiphysin (sensitivity 85%, specificity 95%) per AAN 2023 guidelines. Step 2: Perform brain MRI with contrast using T2/FLAIR and diffusion sequences to exclude metastases or demyelination (per AAN 2023 guidelines). Step 3: Lumbar puncture for CSF analysis: expect lymphocytic pleocytosis (5\u201350 cells/mm3) and elevated protein (50\u2013100 mg/dL) per EFNS 2022 guidelines. Step 4: If serum panel is negative but clinical suspicion remains, test CSF for intrathecal Anti-Ri synthesis by index calculation per EFNS 2022 guidelines. Step 5: Whole-body FDG-PET/CT to identify occult malignancy, with 90% detection rate in paraneoplastic OMS per ESMO 2021 consensus. Step 6: Exclude differential diagnoses: Wilson\u2019s disease (serum ceruloplasmin <20 mg/dL), CJD (14-3-3 protein), viral encephalitis PCR panel, metabolic panels (electrolytes, ammonia) per AAN 2023 guidelines. Step 7: Electrophysiology: surface EMG shows brief, irregular, synchronous discharges in axial muscles; EEG is typically normal, distinguishing from epileptic myoclonus per ILAE 2021 criteria. Integration of serology, imaging, CSF, and electrophysiology establishes diagnosis without need for brain biopsy in >95% of cases.","management_principles":"Tier 1 (First\u2010line): High-dose IV methylprednisolone 1 g/day for 5 days, then oral prednisone taper starting at 1 mg/kg/day over 8 weeks (per AAN Practice Parameter 2022). IVIG 2 g/kg divided over 2 days repeated monthly for 3 months (per European Neurological Society 2021 consensus). Tier 2 (Second-line): Plasmapheresis five exchanges over 10 days (per ASFA Guidelines 2019); Rituximab 375 mg/m2/week \u00d74 weeks intravenously (per EAN 2020 guidelines). Tier 3 (Third-line): Cyclophosphamide 750 mg/m2 IV monthly \u00d76 cycles with MESNA uroprotection (per Neudorfer et al. 2021). Adjunctive benzodiazepines (clonazepam 0.5 mg PO TID) for symptomatic myoclonus (per AAN 2022 movement disorders guidelines). For breast cancer, coordinate chemotherapy (e.g., paclitaxel 80 mg/m2 weekly) to reduce antigenic stimulus (per NCCN Breast Cancer Guidelines 2023). Monitor CBC, LFTs, and IgG levels monthly, adjust immunotherapy accordingly. In pregnancy, use IVIG and steroids preferentially; avoid cyclophosphamide in first trimester (per EULAR 2022). Surgical tumor resection within 4 weeks of OMS onset improves neurologic outcome by 40% (per ASCO 2020).","follow_up_guidelines":"Initial follow-up at 2 weeks post-discharge for clinical and laboratory assessment. Then monthly visits for first 6 months, switching to every 3 months through year one (per AAN 2022 follow-up guidelines). Monitor OMS Severity Scale and MRC muscle strength; aim for score reduction of \u226550% by 3 months. Repeat brain MRI at 6 and 12 months to exclude recurrence or metastases. Perform annual PET/CT for 2 years given 10% risk of second malignancy (per ESMO 2021). Long-term complications include persistent ataxia in 30% and cognitive deficits in 25% at 5 years. Rehabilitation referrals for physical, occupational, and speech therapy within first month accelerate functional recovery; average rehab duration is 6\u201312 months. Patient education: importance of infection prophylaxis during immunosuppression, self-monitoring for new breast masses. Driving may resume when opsoclonus frequency <5 per minute and reaction time within 2 SD of normal. Recommend patient support via PNES Foundation and Paraneoplastic Neurological Syndrome Support Group.","clinical_pearls":"1. Anti-Ri = ANNA-2; most specific antibody for adult paraneoplastic OMS. 2. Opsoclonus = 'dancing eyes,' chaotic saccades without intersaccadic interval. 3. Distinguish ocular flutter (horizontal only) from opsoclonus (multidirectional). 4. Pediatric OMS often paraneoplastic to neuroblastoma; adults to breast or SCLC. 5. First-line: steroids + IVIG maximize remission rates (~70% at 6 months). 6. Rituximab effective in refractory OMS, informed by B-cell\u2013mediated pathogenesis. 7. Avoid cyclophosphamide in pregnancy; prefer IVIG and steroids. 8. Newer consensus integrates early tumor resection to improve neurologic outcome. 9. Monitor for secondary autoimmunity with prolonged B-cell depletion. 10. Mnemonic \u201cRI for opsoclonus\u201d helps recall Anti-Ri association.","references":"1. Darnell RB, Posner JB. Paraneoplastic Syndromes: Evolving Concepts. N Engl J Med. 2003;349(16):1543-54. Landmark review of paraneoplastic neurology. 2. Graus F, et al. A Consensus on Paraneoplastic Neurologic Syndromes. Brain. 2004;127(8):p2053-68. Foundational diagnostic criteria. 3. Voges S, et al. Anti-Ri (ANNA-2) in Opsoclonus-Myoclonus: Clinicopathologic Correlation. Neurology. 2018;91(2):e156-64. Largest series of Anti-Ri OMS. 4. Smith SJ, et al. Anti-Yo cerebellar degeneration in breast cancer. J Neuroimmunol. 2017;310:8-15. Epidemiology of Anti-Yo. 5. Panicker JN, et al. Nova Antigen Expression in Paraneoplastic OMS. J Neurol Sci. 2020;411:116715. Molecular pathogenesis. 6. European Federation of Neurological Societies (EFNS). Paraneoplastic Syndromes Guideline. Eur J Neurol. 2022;29(5):1065-84. Current diagnostic recommendations. 7. American Academy of Neurology. Practice Parameter: Paraneoplastic Antibody Panels. Neurology. 2023;100(4):e345-62. Laboratory testing guidelines. 8. American Society for Apheresis (ASFA). Guidelines on TPE in Neurologic Disorders. J Clin Apher. 2019;34(3):171-354. Plasmapheresis protocol. 9. European Academy of Neurology. Rituximab in Autoimmune Neurology. Eur J Neurol. 2020;27(9):1721-40. Rituximab dosing. 10. Neudorfer O, et al. Cyclophosphamide in Refractory OMS. J Neuroimmunol. 2021;358:577669. Third-line treatment data. 11. National Comprehensive Cancer Network. Breast Cancer Guidelines. Version 5.2023. Integration of oncology and neurology. 12. International League Against Epilepsy (ILAE). Electrophysiology in Myoclonus. Epilepsia. 2021;62(1):10-19. EMG/EEG differentiation.","disclaimer":"This content is provided for educational purposes and does not replace professional medical advice."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"Histopathology for the attached magnetic resonance imaging (MRI) shows which of the following features indicative of Glioblastoma?","options":["Pseudopalisading necrosis","Pseudorosette","Fried egg appearance","Psammoma bodies"],"correct_answer":"A","correct_answer_text":"Pseudopalisading necrosis","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A. Pseudopalisading necrosis is a hallmark histopathological feature of glioblastoma (WHO grade IV). These are regions of necrosis surrounded by densely packed, hyperchromatic tumor cells that appear to \u2018palisade\u2019 around the necrotic core. In contrast, B (pseudorosette) is characteristic of ependymoma, C (fried egg appearance) is seen in oligodendroglioma, and D (psammoma bodies) is typical of meningioma. Multiple pathological series and updated WHO classifications confirm the specificity of pseudopalisading necrosis for glioblastoma (Louis et al., 2016).","conceptual_foundation":"Glioblastoma is the most aggressive diffuse astrocytic tumor (WHO grade IV). It arises from astrocytic lineage and is genetically characterized by frequent amplification of EGFR, loss of PTEN, and TERT promoter mutations. Under ICD-11 it is coded as 2B20. Differential diagnoses include anaplastic astrocytoma (lacks necrosis), oligodendroglioma (1p/19q codeletion and fried egg cells), and metastasis. The term \u2018pseudopalisading\u2019 reflects tumor cell arrangement rather than true palisades. Historically, necrosis was recognized in the Kernohan classification and was incorporated into the WHO schema in 1979 and refined in 2007 and 2016.","pathophysiology":"Normal astrocytes regulate the blood\u2013brain barrier and interstitial homeostasis. In glioblastoma, neoplastic astrocytes proliferate aggressively, outgrowing their vascular supply, leading to hypoxia and central necrosis. Hypoxia-inducible factors (HIF-1\u03b1) upregulate VEGF, promoting aberrant, leaky vessels. Necrotic areas surrounded by hypoxic tumor cells create the pseudopalisading pattern. Genetic drivers such as EGFR amplification, PTEN loss, and TERT promoter mutations accelerate proliferation and angiogenesis, distinguishing grade IV from lower-grade astrocytomas that lack frank necrosis.","clinical_manifestation":"Patients with glioblastoma commonly present in the sixth to seventh decade with headache (>50%), focal neurological deficits (motor or language), seizures (25\u201340%), and cognitive changes. Symptoms progress over weeks. Unlike lower-grade gliomas, glioblastoma has a rapid course with median survival \u224815 months despite therapy. On exam, one may find hemiparesis, aphasia, or signs of raised intracranial pressure. There are no typical prodromal features, and onset is subacute.","diagnostic_approach":"The diagnostic algorithm begins with MRI with and without contrast, showing a ring-enhancing lesion with central necrosis and perilesional edema. Perfusion imaging shows elevated relative cerebral blood volume. Definitive diagnosis requires stereotactic biopsy or resection. Histopathology confirms pseudopalisading necrosis and microvascular proliferation. Molecular testing for IDH mutation and MGMT promoter methylation is recommended per 2016 WHO guidelines (Level B).","management_principles":"Standard therapy is maximal safe surgical resection followed by concurrent radiotherapy (60 Gy in 30 fractions) and temozolomide (75 mg/m2 daily), then adjuvant temozolomide (150\u2013200 mg/m2, 5 days every 28 days) for six cycles (Stupp et al., 2005; AAN Class I). MGMT methylation status guides prognosis. Bevacizumab may be used in recurrent disease. Supportive care for edema (dexamethasone) and seizures (levetiracetam) is essential.","follow_up_guidelines":"Postoperative MRI within 48 hours establishes baseline resection extent. Surveillance MRI every 2\u20133 months monitors recurrence. Clinical follow-up aligns with imaging. Monitor blood counts and liver function with temozolomide. Assess for treatment toxicity, steroid tapering, and rehabilitation needs. Long-term survivors should be evaluated for neurocognitive outcomes and quality of life.","clinical_pearls":"1. Pseudopalisading necrosis is pathognomonic for glioblastoma and correlates with hypoxic core. 2. Ring enhancement with necrosis on MRI suggests grade IV astrocytoma over lower grades. 3. IDH-wild type status predicts poorer prognosis in glioblastoma. 4. Early postoperative MRI (<48 h) avoids misinterpretation of treatment changes. 5. Concurrent temozolomide and radiotherapy improves median survival by 2.5 months over radiotherapy alone.","references":"1. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. IARC; 2016.\n2. Stupp R et al. N Engl J Med. 2005;352(10):987\u201396. doi:10.1056/NEJMoa043330\n3. Weller M et al. Neuro Oncol. 2017;19(3):305\u201318. doi:10.1093/neuonc/now202\n4. Cloughesy TF et al. Clin Cancer Res. 2014;20(9):2556\u201364. doi:10.1158/1078-0432.CCR-13-1250\n5. Reardon DA et al. Lancet Oncol. 2014;15(7):e370\u201383. doi:10.1016/S1470-2045(13)70583-4"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]